Treating very preterm European infants with inhaled nitric oxide increased in-hospital mortality but did not affect neurodevelopment at 5 years of age.

Autor: Siljehav V; Department of Women's & Children's Health, Karolinska Institutet, Stockholm, Sweden., Gudmundsdottir A; Department of Women's & Children's Health, Karolinska Institutet, Stockholm, Sweden., Tjerkaski J; Department of Women's & Children's Health, Karolinska Institutet, Stockholm, Sweden., Aubert AM; INSERM UMR 1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epopé), Center for Epidemiology and Statistics Sorbonne Paris Cité, DHU Risks in pregnancy, Paris Descartes University, Paris, France., Cuttini M; Clinical Care and Management Innovation Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Koopman C; Division of Perinatology and Gynaecology, University Medical Centre Utrecht, Utrecht, The Netherlands., Maier RF; Children's Hospital, University Hospital, Philipps University Marburg, Marburg, Germany., Zeitlin J; INSERM UMR 1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epopé), Center for Epidemiology and Statistics Sorbonne Paris Cité, DHU Risks in pregnancy, Paris Descartes University, Paris, France., Åden U; Department of Women's & Children's Health, Karolinska Institutet, Stockholm, Sweden.
Jazyk: angličtina
Zdroj: Acta paediatrica (Oslo, Norway : 1992) [Acta Paediatr] 2024 Mar; Vol. 113 (3), pp. 461-470. Date of Electronic Publication: 2023 Dec 23.
DOI: 10.1111/apa.17075
Abstrakt: Aim: We examined the outcomes of using inhaled nitric oxide (iNO) to treat very preterm born (VPT) infants across Europe.
Methods: This was a sub-study of the Screening to Improve Health in Very Preterm Infants in Europe research. It focused on all infants born between 22 + 0 and 31 + 6 weeks/days of gestation from 2011 to 2012, in 19 regions in 11 European countries. We studied 7268 infants admitted to neonatal care and 5 years later, we followed up the outcomes of 103 who had received iNO treatment. They were compared with 3502 propensity score-matched controls of the same age who did not receive treatment.
Results: All countries used iNO and 292/7268 (4.0%) infants received this treatment, ranging from 1.2% in the UK to 10.5% in France. There were also large regional variations within some countries. Infants treated with iNO faced higher in-hospital mortality than matched controls (odds ratio 2.03, 95% confidence interval 1.33-3.09). The 5-year follow-up analysis of 103 survivors showed no increased risk of neurodevelopmental impairment after iNO treatment.
Conclusion: iNO was used for VPT patients in all 11 countries. In-hospital mortality was increased in infants treated with iNO, but long-term neurodevelopmental outcomes were not affected in 103 5-year-old survivors.
(© 2023 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica.)
Databáze: MEDLINE
Externí odkaz: